1. Medtech Insight
  2. >>Policy & Regulation

CMS Contractors Propose LCD Payments For Inspire Medical’s Sleep Apnea Nerve Stimulation Device

 
• By Sue Darcey

Noridian and Palmetto – two Medicare administrative contractors (MACs) serving 19 states in the West and Southeast – on 26 August proposed local coverage determinations (LCDs) for Inspire Medical Systems Inc.’s hypoglossal nerve stimulation devices to treat obstructive sleep apnea.

Inspire Therapy

Medicare administrative contractors for 19 US states have proposed supplying local Medicare coverage for hypoglossal nerve stimulation (HNS) provided by Inspire Medical Systems’ Inspire therapy to treat obstructive sleep apnea (OSA).

Noridian (which reimburses Medicare patients in Alaska, Arizona, California, Hawaii, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington and Wyoming) and Palmetto (which provides Medicare coverage for seven states...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.